HIPEC Improves Long-Term Outcomes in Stage III Ovarian Cancer
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
Diagnosis & Disease Information
Increased Exposure to PFAS, Phenols Linked to Prior Cancer Diagnosis
Greater PFDE, PFNA, and PFUA associated with increased odds of previous melanoma.
Immune Checkpoint Inhibitor-Induced LVEF Decreases Rare in Ovarian Cancer
Left ventricular ejection fraction data from the JAVELIN Ovarian 200 trial showed low cardiotoxicity in patients with ovarian cancer treated with avelumab, avelumab plus PLD, or PLD.
Screening Confers “Small” Survival Benefit in High-Grade Serous Ovarian Cancer
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
Oncology Nurse Awareness of Targeted Therapy for Ovarian Cancer Limited
A study determined oncology nurses are aware of biomarker testing and targeted therapy for ovarian cancer but seemed less aware of their specific details.
Discontinuation of Bevacizumab in Ovarian Cancer May Result in Rebound
Bevacizumab can reduce the risk of progression in patients with ovarian cancer for about 1 year after treatment initiation, but discontinuing the drug increases the risk of progression, researchers found.
Are Specific Occupational Exposures Linked to Ovarian Cancer?
Increased odds ratios observed for employment as accountants; hairdressers, beauticians, and related workers; sewers and embroiderers.
Artificial Intelligence Has Great Potential in Oncology Nursing, More Research Needed
Researchers sought to determine whether AI could improve oncology nursing for patients with cancer.
How to Treat Gynecologic Cancers During the Chemotherapy Shortage
SGO, FWC, and GOG-F have released recommendations for how to treat patients with gynecologic cancers in light of current chemotherapy shortages.
Incorporating Durvalumab and Olaparib Into Ovarian Cancer Treatment Improves PFS
Adding durvalumab to first-line therapy and adding durvalumab and olaparib to maintenance improves PFS in patients with ovarian cancer, phase 3 data suggest.
- Loading...
Loading...
Next post in Ovarian Cancer
Loading... 
Loading...